05-06-2026 18:55 via medpagetoday.com

B-Cell Depleter Nabs Phase III Win in Autoimmune Kidney Disease

(MedPage Today) -- The B-cell depleting agent obinutuzumab (Gazyva) was superior to the immunosuppressant tacrolimus in inducing remissions in primary membranous nephropathy, the global phase III MAJESTY trial showed.
By week 104, 37% of patients...
Read more »

Medical Industry news



CDC Sees 10,000 Ebola Deaths Among Possible Outbreak Scenarios
One Surgical Technique for Cervical Lesions May Reduce Recurrences
Senator Cassidy Calls Out RFK Jr.
Finerenone Also Slows Kidney Decline in Diabetes-Free Patients
What Virus Now Faces a New FDA Approval?
How Much Prednisone Is Too Much in Treating Rheum Effects From Cancer Therapies?
ICE to No Longer Report Deaths of Detainees Recently Released From Custody
Aspirin and Bladder Cancer; Oncology Workforce Shortage; 'Exploding Immune Cells'
Novel Lupus Drugs Continue to Shine in Extended Early Data
Video: Police Tussle With Diabetes Experts at ADA Meeting
The World Cup Is Coming. Here’s What EDs Should Prepare For.
Ebola in Congo: What Happens When Global Response Capacity Disappears?
Politicization of Grants; Lessons From the 2014 Ebola Outbreak; Hantavirus Update
Deadly Cheese-Linked Outbreak; 15 Med Schools Probed; 'Concern' on FDA Voucher Pilot
Desktop versie